Introduction
============

Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in people older than 50 y of age in the developed world ([@b1-etm-0-0-6305]). Although the neovascular form accounts for only 20% of AMD cases, it is the main cause of severe vision loss in almost 90% of patients with AMD ([@b2-etm-0-0-6305],[@b3-etm-0-0-6305]). Choroidal neovascularization (CNV) is the primary pathology underlying wet AMD and is a pathological form of neovascularization that can cause bleeding, hemorrhage, fibrosis, and retinal pigment epithelium and neurosensory functional damage, eventually resulting in vision loss ([@b4-etm-0-0-6305]).

At present, there are many treatments available for AMD. The most common treatments are verteporfin photodynamic therapy (PDT) and anti-vascular endothelial growth factor (VEGF) drugs administered via intraocular injection ([@b5-etm-0-0-6305]). Bevacizumab is a humanized anti-VEGF monoclonal IgG1 antibody that binds to all isoforms of VEGF and can therefore prevent angiogenesis ([@b6-etm-0-0-6305]). Off-label use of bevacizumab has been shown to be reasonably safe and very effective in the treatment of AMD ([@b7-etm-0-0-6305]--[@b9-etm-0-0-6305]). Several studies have shown that bevacizumab and ranibizumab have equivalent efficacy and comparable safety ([@b10-etm-0-0-6305]--[@b15-etm-0-0-6305]). Bevacizumab is still widely used for this off-label indication not only because it has a mode of action similar to that of ranibizumab but also because its cost is considerably lower than that of ranibizumab ([@b16-etm-0-0-6305],[@b17-etm-0-0-6305]). However, bevacizumab monotherapy requires multiple reinjections ([@b18-etm-0-0-6305]) and is associated with the risk of endophthalmitis, cataract formation and uveitis ([@b19-etm-0-0-6305]--[@b23-etm-0-0-6305]), as well as an increased risk of thromboembolic events ([@b24-etm-0-0-6305]).

PDT with verteporfin has historically been the standard treatment for AMD and has been shown to benefit patients affected by classic CNV in the setting of AMD ([@b25-etm-0-0-6305]--[@b27-etm-0-0-6305]). Combining PDT with bevacizumab may reduce the number of required treatments and preserve or even enhance visual acuity. Increasing numbers of studies have reported that PDT combined with intravitreal bevacizumab is an effective option for patients with AMD, as this combination facilitates improvements in visual acuity, decreases in central retinal thickness (CRT) and reductions in the number of retreatments ([@b28-etm-0-0-6305]--[@b31-etm-0-0-6305]). Studies comparing combination therapy with monotherapy have reported that combination therapy significantly improves visual acuity compared to monotherapy ([@b32-etm-0-0-6305]). However, the ideal maintenance regimen for this combination remains an area of scientific debate. Four clinical randomized controlled trials (RCTs) showed that there were no significant differences in visual gain between patients receiving the combination of PDT and bevacizumab and patients receiving monotherapy, although these studies found that the combination of the two agents reduced reinjection rates ([@b30-etm-0-0-6305],[@b33-etm-0-0-6305]--[@b35-etm-0-0-6305]).

Therefore, we performed a meta-analysis of RCTs to compare the efficacy and safety of the combination of verteporfin PDT and intravitreal bevacizumab therapy with those of bevacizumab monotherapy in patients with AMD.

Materials and methods
=====================

### Search strategy

A systematic English language search of PubMed, EMBASE and the Cochrane Central Register of Controlled Trials for human studies published up to October 2017 was conducted, with language restrictions. Key terms included AMD, bevacizumab, avastin and PDT. The search was restricted to RCTs. We manually searched the reference lists of all original studies and review articles identified by the electronic search to identify other potentially eligible articles.

### Inclusion criteria

We selected the following studies: i) studies including patients with active CNV secondary to AMD; ii) studies featuring a randomized controlled trial (RCT) design comparing the combination of bevacizumab and PDT with bevacizumab monotherapy and iii) studies measuring at least one outcome of interest.

### Exclusion criteria

The following studies were excluded: i) studies that were not RCTs; ii) studies of CNV not caused by AMD and iii) unpublished conference abstracts.

### Data extraction and quality assessment

Titles and abstracts were reviewed by two reviewers using the above selection criteria. Full-text versions of all relevant studies were obtained for detailed evaluations. Data extraction and quality assessments were conducted using the modified Jadad assessment tool ([@b36-etm-0-0-6305]). Disagreements were resolved via consensus after discussion. The following data were extracted from each study: the name of the first author, the study design, and the major inclusion and exclusion criteria, as well as information regarding study population characteristics (age, sex, no. of eyes in the study), intervention groups, follow-up durations and outcomes (ocular and systemic adverse effects). Data regarding changes in best-corrected visual acuity (BCVA), the numbers of patients with gains of more than 15 letters, the average numbers of bevacizumab retreatments, and changes in CRT were also extracted.

### Statistical analysis

The meta-analysis was conducted using RevMan v.5.3 software. Risk ratios (RRs) were measured using 95% confidence intervals (CIs) for dichotomous data, while weighted mean differences (WMDs) were measured using 95% CIs for continuous data. Standard mean differences (SMDs) were used when all the trials assessed the same outcomes in a variety of ways. The Q test or I^2^ test was used to evaluate heterogeneity. An I^2^ value of \>50% accompanied with a P-value \<0.05 for the Q test was determined to indicate the presence of significant heterogeneity. Both fixed-effects and random-effects models were used to obtain summary RRs, WMDs or SMDs. In the absence of heterogeneity between groups, the fixed-effects model and random-effects model yielded concordant results. When heterogeneity was significant, the random effects model was employed. Potential publication bias was estimated using the Egger test and by visually evaluating a funnel plot.

Results
=======

### Literature search

A flow chart of the selection process used to identify eligible studies is shown in [Fig. 1](#f1-etm-0-0-6305){ref-type="fig"}. A total of 205 articles were initially identified. After duplicates were screened for potentially relevant articles, 194 articles were deemed eligible for further evaluation. We screened the titles and abstracts of these articles and identified 6 eligible studies. We subsequently read the text of each article and found 1 from the same study group, which was excluded. Ultimately, five published ([@b30-etm-0-0-6305],[@b32-etm-0-0-6305]--[@b35-etm-0-0-6305]) articles were eligible for analysis.

### Included studies

The basic characteristics of the five included studies are shown in [Table I](#tI-etm-0-0-6305){ref-type="table"}. Sample sizes ranged from 23 to 106 eyes. Mean patient ages ranged from 63.2 to 83.4 years. The dose of bevacizumab was 1.25 mg in the bevacizumab monotherapy groups of the included studies. The doses of verteporfin PDT and bevacizumab were 25 J/cm^2^ standard fluence (SF) and 1.25 mg, respectively, in the combination therapy groups of the included studies, with the exception of the Lazic and Gabric ([@b32-etm-0-0-6305]) study, in which the dose of PDT was not mentioned. Moreover, the duration of follow-up varied from 3 to 12 months among the studies. The five studies were assessed regarding methodological quality, according to the Jadad score and were determined to be of high quality.

Estimation of outcomes
----------------------

### Changes in mean BCVA compared with baseline

Visual acuity was the most important outcome measure with respect to treatment efficacy. The results regarding changes in mean BCVA are shown in [Fig. 2A](#f2-etm-0-0-6305){ref-type="fig"}. There were no significant differences in changes in BCVA between the combination group and bevacizumab group (SMD 0.20; 95% CI −0.53, 0.93, P=0.59). The random-effects model was used due to the high heterogeneity of the effect size (I^2^=91%, P\<0.00001). The dose of PDT is not mentioned in Lazic and Gabric ([@b32-etm-0-0-6305]) study and this may have heterogeneous. So we removed the Lazic and Gabric ([@b32-etm-0-0-6305]) study to apply the sensitivity analysis and found that the result of statistical analysis was still insignificant (SMD, −0.11; 95% CI −0.35, 0.13, P=0.39; [Fig. 2B](#f2-etm-0-0-6305){ref-type="fig"}).

### Number of patients who gained more than 15 letters

We extracted the number of patients who gained more than 15 letters. Because the data were not heterogeneous (I^2^=0%, P=0.78), the fixed-effects model was used. The pooled RR showed that there was no significant difference between the two intervention groups regarding the number of patients who gained more than 15 letters (RR 0.86, 95% CI 0.64, 1.15, P=0.30; [Fig. 3](#f3-etm-0-0-6305){ref-type="fig"}).

### CRT

CRT is the most important anatomical change associated with AMD treatment. The effects of the combination of bevacizumab and PDT on CRT compared with those of bevacizumab monotherapy are shown in [Fig. 4](#f4-etm-0-0-6305){ref-type="fig"}. The pooled results indicate that there was no significant difference between the two groups regarding changes in CRT (WMD −22.16, 95% CI −52.01 to 7.69, P=0.15).

### Average number of bevacizumab retreatments

Three studies measured the average number of bevacizumab retreatments. The pooled results indicate that the average number of bevacizumab retreatments was significantly lower in the combination therapy group than in the bevacizumab monotherapy group (WMD −2.70, 95% CI −3.93 to −1.46, P\<0.0001; [Fig. 5](#f5-etm-0-0-6305){ref-type="fig"}). The random-effects model was used due to the high heterogeneity of the effect size (I^2^=95%, P\<0.00001).

### Adverse events

Four ([@b30-etm-0-0-6305],[@b32-etm-0-0-6305],[@b34-etm-0-0-6305],[@b35-etm-0-0-6305]) of five studies \[excluding Datseris *et al* ([@b33-etm-0-0-6305])\] reported data regarding ocular adverse events and systematic adverse events. We compared the numbers of ocular adverse events and non-ocular adverse events in the combination group with those in the bevacizumab monotherapy group and noted that four were no significant differences between the two intervention groups with respect to those parameters ([Fig. 6](#f6-etm-0-0-6305){ref-type="fig"}). All adverse events reported in the abovementioned three studies are shown in [Table II](#tII-etm-0-0-6305){ref-type="table"}.

### Heterogeneity, sensitivity analysis, and publication bias

The dose of PDT is not mentioned in one study and this may have heterogeneous. After excluding the study, the analysis results not changed. A sensitivity analysis was conducted to assess the stability of the results by sequential removal of individual studies. When the analysis result is high heterogeneity, we use random effects model. These sensitivity analyses indicated that our conclusions were generally robust. Funnel plots and Egger test were not used because there were less than ten studies for each comparison.

Discussion
==========

In this meta-analysis, we assessed four RCTs including 371 patients (183 patients in the combination group and 188 patients in the bevacizumab group). Lazic and Gabric ([@b32-etm-0-0-6305]), noted significant improvements in BCVA at 3 months after combination therapy with verteporfin PDT and intravitreal bevacizumab. Some studies observed that there was no significant differences in visual acuity improvement between the bevacizumab monotherapy group and combination therapy group ([@b30-etm-0-0-6305],[@b33-etm-0-0-6305]--[@b35-etm-0-0-6305]). The results of our meta-analysis indicated that the bevacizumab monotherapy group experienced improvements in BCVA similar to those of the combination therapy group, indicating that the efficacies of the two therapy regimens were similar with respect to this parameter. We assessed the numbers of patients who gained more than 15 letters and determined that there was no significant difference between two groups with respect to this parameter. Regarding mean changes in CRT, bevacizumab monotherapy demonstrated efficacy equivalent to that of combination therapy. PDT does not have a destructive impact on patient vision, as is the case with older treatments, and stabilizes wet AMD progression ([@b37-etm-0-0-6305]). However, the combination of PDT and bevacizumab can result in more rapid and permanent CNV occlusion ([@b8-etm-0-0-6305]), resulting in increased ocular VEGF levels ([@b38-etm-0-0-6305]). These findings may explain the similar efficacies exhibited by the two treatment regimens.

Reinjection rates were significantly lower in patients treated with combination therapy than in patients treated with bevacizumab monotherapy. In this meta-analysis, we noted that the average number of bevacizumab reinjections in the combination group was lower than that in the bevacizumab monotherapy group. These findings support the hypothesis that combination treatment exerts synergistic effects, resulting in a reduced need for subsequent injections compared with monotherapy. Thus, combination therapy may be a more cost-effective option than monotherapy for the treatment of neovascular AMD.

The included RCTs indicated that both treatments were safe. The majority of adverse events associated with bevacizumab monotherapy and combination treatment were of moderate severity. No serious adverse events, such as death or endophthalmitis, were noted in any of the included RCTs. One patient died of a stroke ([@b34-etm-0-0-6305]). Ocular adverse events occurred more frequently in the bevacizumab monotherapy group than in the combination therapy group, most likely due to the use of intravitreal injections in the former group. The most significant side effects associated with the two treatments were posterior vitreous detachments and cataracts. Other side effects, such as increased anterior chamber cell pigment epithelium tears and vision loss of more than 20 letters, were reported in three studies. However, there was no difference in the incidence of ocular adverse events between the two groups. Systemic adverse events, such as hypertension and myocardial infraction, were reported only in the combination therapy group of one study ([@b34-etm-0-0-6305]). We noted no significant difference in the incidence of adverse events between the two groups, findings consistent with those of related clinical trials. However, as the number of studies included in our analysis was small, additional RCTs comparing the efficacy and safety of bevacizumab monotherapy and combination therapy among larger groups of patients are necessary to confirm our findings.

This meta-analysis had some limitations. Verteporfin PDT has been shown to be more effective at treating classic choroidal neovascularization than mild or classic occult CNV, and this analysis did not examine its efficacy with respect to the different types of CNV. Thus, additional studies are required. Furthermore, the differences in the durations of the included trials (3 to 12 months) were a potential source of heterogeneity. Some studies did not provide means and standard deviations, electing to report only before- and after-treatment values or medians and ranges, which may have resulted in data conversion-related errors. Finally, the numbers of bevacizumab treatments administered in the included trials were not uniform, as the average numbers of bevacizumab injections differed among the studies. Additionally, the dose of PDT was not mentioned in one of the included studies, which have may have biased our results. And the small number of studies included in this meta-analysis was a limitation of the study, and that publication bias could therefore not be assessed.

In conclusion, there were no significant differences in mean BCVA changes, CRT increases, the proportions of patients gaining more than 15 letters, or the incidences of ocular adverse events and systemic adverse events between the two groups. However, combination therapy may significantly reduce the average number of bevacizumab retreatments compared with monotherapy. And this systematic review and meta-analysis may provide a basis for clinical treatment of wet AMD.
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###### 

Study characteristics of the included four RCTs.

  Author (Ref.)                                  Design   Inclusion criteria                                                      Sex (M/F)                                      Mean age, years                             No. of eyes                           Intervention groups                                               Follow-up (months)   Jadad score
  ---------------------------------------------- -------- ----------------------------------------------------------------------- ---------------------------------------------- ------------------------------------------- ------------------------------------- ----------------------------------------------------------------- -------------------- -------------
  Costagliola 2010, ([@b30-etm-0-0-6305])        RCT      Naïve classic or predominantly classic subfoveal CNV secondary to AMD   All: 38/47                                     Group 1: 65.3 Group 2: 63.2                 Group 1: 45 Group 2: 40               Group 1: IVB (1.25 mg) Group 2: IVB (1.25 mg) +PDT (25 J/cm^2^)   12                   3
  Datseris 2015, ([@b33-etm-0-0-6305])           RCT      Predominantly classic and occult CNV due to AMD                         All: 29/66                                     Group 1: 74 Group 2: 73                     Group 1: 46 Group 2: 49               Group 1: IVB (1.25 mg) Group 2: IVB (1.25 mg) +PDT (25 J/cm^2^)   12                   3
  Lazic and Gabric 2007, ([@b32-etm-0-0-6305])   RCT      Minimally classic or occult CNV due to AMD                              Group 1: 17/37 Group 2: 18/34 Group 3: 15/35   Group 1: 76.1 Group 2: 75.4 Group 3: 75.6   Group 1: 54 Group 2: 52 Group 3: 50   Group 1:IVB (1.25 mg) Group 2: IVB (1.25 mg) Group 3: PDT         3                    4
  Potter 2010, ([@b34-etm-0-0-6305])             RCT      New-onset CNV secondary to AMD                                          Group 1: 3/8                                   Group 1: 83.4                               Group 1: 11                           Group 1: IVB (1.25 mg) +PDT (25 J/cm^2^)                            6                  5
                                                                                                                                  Group 2: 4/8                                   Group 2: 78.3                               Group 2: 12                           Group 2: IVB (1.25 mg) +PDT (12 J/cm^2^)                                               
                                                                                                                                  Group 3: 4/8                                   Group 3: 80.6                               Group 3: 12                           Group 3: IVB (1.25 mg) +sham PDT                                                       
  Saviano 2016, ([@b35-etm-0-0-6305])            RCT      AMD-related CNV                                                         Group 1: 9/22 Group 2: 12/19                   Group 1: 77 Group 2: 31                     Group 1: 31 Group 2: 31               Group 1: IVB (1.25 mg) Group 2: IVB (1.25 mg) +PDT (25 J/cm^2^)   12                   2

RCT, randomized controlled trials; CNV, choroidal neovascularization; IVB, intravitreal bevacizumab; AMD, age-related macular degeneration; PDT, photodynamic therapy.

###### 

Main ocular adverse events and systemic adverse events reported in the three studies.

                                                              Combination   Bevacizumab                   
  ----------------------------------------------------------- ------------- ------------- ----- --- ----- -----
  Ocular adverse events                                                                                   
    Pigment epithelium tears                                  0             103           0     3   111   2.7
    Posterior vitreous detachments                            4             103           3.9   8   111   7.2
    Cataract progressions                                     3             103           2.9   4   111   3.6
    Vision loss ≥20 letters                                   1             103           1     0   111   0
    Non-ocular adverse events                                 1             103           1     0   111   0
    Hypertension                                              1             103           1     0   111   0
    Myocardial infraction                                     1             103           1     0   111   0
    Mortality^[a](#tfn2-etm-0-0-6305){ref-type="table-fn"}^                                               

One subject had a stroke and succumbed to mortality.
